Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma

Oncology ◽  
2018 ◽  
Vol 95 (3) ◽  
pp. 170-178 ◽  
Author(s):  
Takuya Owari ◽  
Makito Miyake ◽  
Yasushi Nakai ◽  
Yosuke Morizawa ◽  
Yoshitaka Itami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Bone Metastasis ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Renal Cell ◽  
Genitourinary Cancer ◽  
Skeletal Related Events

Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis

2018 ◽  
Vol 23 (6) ◽  
pp. 1127-1133 ◽  
Author(s):  
Seiichi Hosaka ◽  
Hirohisa Katagiri ◽  
Masashi Niwakawa ◽  
Hideyuki Harada ◽  
Junji Wasa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Skeletal Related Events

The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis

2014 ◽  
Vol 191 (6) ◽  
pp. 1678-1684 ◽  
Author(s):  
Carina Antczak ◽  
Vincent Q. Trinh ◽  
Akshay Sood ◽  
Praful Ravi ◽  
Florian Roghmann ◽  
...  
Keyword(s):  
Health Care ◽  
Renal Cell Carcinoma ◽  
Bone Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Care Burden ◽  
Health Care Burden ◽  
Skeletal Related Events

scholarly journals The Value of Urinary RBP4 in The Diagnosis of FSGS and other Renal Diseases.

2020 ◽  
Author(s):  
Karolina Marek-Bukowiec ◽  
Andrzej Konieczny ◽  
Krzysztof Ratajczyk ◽  
Katarzyna Macur ◽  
Paulina Czaplewska ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Renal Cell ◽  
Healthy Subjects ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Healthy Controls ◽  
Retinol Binding Protein 4

Abstract BackgroundFocal segmental glomerulosclerosis (FSGS) is the leading cause of chronic renal failure worldwide. Unequivocal diagnosis of FSGS can only be made with a renal biopsy, which is an invasive, risk-associated medical procedure. The discovery of non-invasive molecular biomarkers for the diagnosis of FSGS still remains an important scientific goal. This study examines the urinary proteome profile of FSGS patients and reference groups, in order to identify urinary protein expression alterations indicative of FSGS. Methods Urine samples were collected from subjects representing FSGS, IgA nephropathy (IgAN), clear cell renal cell carcinoma (ccRCC), chromophobe renal cell carcinoma (chRCC), and healthy control group, respectively. The samples were pooled and subjected to SWATH-MS proteomics analysis. ELISA was utilized to validate the expression level of Retinol-binding protein 4 (uRBP4) in 130 urine supernatant samples (21 FSGS, 20 IgAN, 31 ccRCC, 21 chRCC, 7 prostate cancer patients and 30 healthy volunteers).ResultsThe MS study identified 194 (FSGS), 179 (IgAN), 271 (ccRCC), 255 (chRCC), and 275 (healthy controls) urinary proteins. The comparative proteomic analysis revealed that Retinol-binding protein 4 clearly discriminates FSGS from the rest of the groups. Increased levels of uRBP4 in FSGS urine specimens were also detected by ELISA (FSGS vs IgAN p=0.0244, FSGS vs ccRCC p=0.004, FSGS vs chRCC p=0.013, FSGS vs prostate cancer p=0.02, FSGS vs healthy controls p<0.00001). Significantly elevated levels of uRBP4 were also observed for IgAN, ccRCC and chRCC versus healthy individuals.ConclusionsUrinary RBP4 protein is significantly upregulated in FSGS in comparison to IgAN, ccRCC, chRCC, prostate cancer patients and healthy subjects. Determining FSGS diagnosis based on uRBP4 expression alone is not possible. Specific uRBP4 concentration cut-off can be applied to accurately distinguish individuals with renal disorder (in general) from healthy subjects. Thus, urinary RBP4 could serve as a screening biomarker identifying people at risk of renal disorders, who should undergo more detailed diagnostics.

Clinical features and outcomes of tumor lysis syndrome in patients with genitourinary cancers.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 533-533
Author(s):  
Jue Wang ◽  
Bryan Leung
Keyword(s):  
Prostate Cancer ◽  
Renal Cell Carcinoma ◽  
Liver Metastasis ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Features ◽  
Renal Cell ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Genitourinary Cancers

533 Background: Genitourinary (GU) cancers account about 20% of all human cancer in the United States. Tumor lysis syndrome (TLS) is an oncologic emergency with few treatment options. While TLS has been extensively documented in patients with hematological malignancies, it is rarely described in patients with GU cancers. The objective of this study was to investigate the clinical characteristics and outcomes of TLS, a rare but life-threatening complication in GU cancers. Methods: Systematic review of the literature and pooled analysis of published cases of TLS in GU cancers. Results: A total of 180 patients with TLS in solid tumor were included in our study. The median age was 57 years (8-94). Male: female ratio was 1.7. The most common sites were gastrointestinal (29%); followed by genitourinary (22%); lung (16%); melanoma (11%), breast cancer (8.3%). Liver metastasis was documented in 70% of study subjects. TLS occurred as a consequence of cancer therapy in 68% of subjects; and spontaneously in 32% of subjects. Older age and liver metastasis predict high mortality. The clinical features, treatment and outcomes of TLS in 40 cases of GU cancers including testicular germ cell tumor (TGCT) (n=14), renal cell carcinoma (n=10), prostate cancer (n=15), penile cancer (n=1) and urothelial carcinoma (n=3) were compared. The mortality rate of TLS were 50% in TGCT, 70% in renal cell carcinoma, 64% in prostate cancer 67% in urothelial carcinoma. Conclusions: TLS in GU cancers is associated with very high mortality. TLS should be considered on the differential diagnosis, when evaluating renal failure and electrolyte derangement in patients with metastatic GU cancers with liver metastases. The clinical features and outcomes of TLS in genitourinary cancers. [Table: see text]

264: Population-Based Study of Renal Cell Carcinoma and Prostate Cancer in the Same Patient

2005 ◽  
Vol 173 (4S) ◽  
pp. 73-73 ◽  
Author(s):  
Daniel A. Barocas ◽  
Farhang Rabbani ◽  
Douglas S. Scherr ◽  
E. Darracott Vaughan
Keyword(s):  
Prostate Cancer ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Population Based ◽  
Population Based Study

scholarly journals A convention-radiomics CT nomogram for differentiating fat-poor angiomyolipoma from clear cell renal cell carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yanqing Ma ◽  
Weijun Ma ◽  
Xiren Xu ◽  
Zheng Guan ◽  
Peipei Pang
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Logistic Model ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Entire Cohort ◽  
Conventional Ct ◽  
Radiomics Signature

AbstractThis study aimed to construct convention-radiomics CT nomogram containing conventional CT characteristics and radiomics signature for distinguishing fat-poor angiomyolipoma (fp-AML) from clear-cell renal cell carcinoma (ccRCC). 29 fp-AML and 110 ccRCC patients were enrolled and underwent CT examinations in this study. The radiomics-only logistic model was constructed with selected radiomics features by the analysis of variance (ANOVA)/Mann–Whitney (MW), correlation analysis, and Least Absolute Shrinkage and Selection Operator (LASSO), and the radiomics score (rad-score) was computed. The convention-radiomics logistic model based on independent conventional CT risk factors and rad-score was constructed for differentiating. Then the relevant nomogram was developed. Receiver operation characteristic (ROC) curves were calculated to quantify the accuracy for distinguishing. The rad-score of ccRCC was smaller than that of fp-AML. The convention-radioimics logistic model was constructed containing variables of enhancement pattern, VUP, and rad-score. To the entire cohort, the area under the curve (AUC) of convention-radiomics model (0.968 [95% CI 0.923–0.990]) was higher than that of radiomics-only model (0.958 [95% CI 0.910–0.985]). Our study indicated that convention-radiomics CT nomogram including conventional CT risk factors and radiomics signature exhibited better performance in distinguishing fp-AML from ccRCC.

18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma

2014 ◽  
Vol 35 (12) ◽  
pp. 1247-1253 ◽  
Author(s):  
Punit Sharma ◽  
Sellam Karunanithi ◽  
Partha S. Chakraborty ◽  
Rajeev Kumar ◽  
Amlesh Seth ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastasis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pet Ct ◽  
18F Fluoride

scholarly journals Synchronous ipsilateral renal cell carcinoma and urothelial carcinoma of the renal pelvis

2013 ◽  
Vol 3 (1) ◽  
pp. 64 ◽  
Author(s):  
Mike Leveridge ◽  
Phillip A. Isotalo ◽  
Alexander H. Boag ◽  
Jun Kawakami
Keyword(s):  
Renal Cell Carcinoma ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Renal Pelvis ◽  
Renal Cell ◽  
Preoperative Imaging ◽  
Time Of Surgery ◽  
Urological Malignancies ◽  
Carcinome Urothélial ◽  
Fresh Specimen

Renal cell carcinoma (RCC) and urothelial carcinoma of the upperurinary tract are not uncommon urological malignancies. Theirsimultaneous occurrence in a patient is, however, extraordinarilyrare. We report the case of a patient who underwent laparoscopicnephrectomy for suspected RCC. Preoperative imaging wassuspicious for renal pelvic involvement, which was confirmedupon bivalving the fresh specimen at the time of surgery, with thediscovery of a separate urothelium-based lesion. We discuss thisrare occurrence and our management approach.Individuellement, l’hypernéphrome et le carcinome urothélial desvoies urinaires supérieures ne sont pas des tumeurs urologiquesrares. Leur survenue simultanée chez un même patient est cependantextrêmement rare. La reconnaissance préopératoire ou intraopératoireest cruciale afin que soit effectuée la résection urétéralerequise. Nous décrivons un cas d’hypernéphrome et de carcinomeurothélial simultanés et homolatéraux.

Sign in / Sign up

Export Citation Format

Share Document